General Proximity Secures Strategic Investment to Advance Proximity-Based Drug Discovery Platform
General Proximity just pulled in fresh capital from FreeMind Investments and Daewoong Pharmaceutical Co., Ltd., and like any deal where the science is ahead of the headlines, the number stays quiet while the signal gets loud.
Founded in 2019 in San Francisco by Armand B. Cognetta III, PhD, the company is chasing something most of pharma has learned to walk around instead of through: undruggable targets. Cancer, cardiometabolic disease, neurodegeneration, longevity. The kind of list that makes investors either lean in or politely change the subject. FreeMind and Daewoong leaned in.
At the center is OmniTAC, General Proximity’s mechanism-agnostic proximity discovery engine. The pitch is simple, the execution is not. Instead of forcing biology to cooperate, the platform identifies how proteins can be brought into proximity to trigger a therapeutic effect. It is less about brute force and more about choreography at the molecular level, scanning the effectome for interactions most approaches never even consider.
The capital stack tells its own story. More than $20 million raised to date. A $16 million de-stealth moment. An $8 million seed led by Aydin Senkut at Felicis. Backing from Y Combinator, Jim Dahl of Rock Creek, age1, Modi Ventures, Wilson Sonsini. Non-dilutive support from ARPA-H and the NIH National Cancer Institute. A multi-target oncology collaboration with Daiichi Sankyo. Then this latest move, with FreeMind Investments and Daewoong Pharmaceutical stepping into the frame with clear strategic gravity.
Inside the company, the leadership core is tight and technical. Armand B. Cognetta III, PhD sets the direction. Timothy Herpin, PhD drives business strategy. Andreas Maderna, PhD leads drug discovery and chemistry. Daniela Y. Santiesteban, PhD connects program execution with business development. Around them sits a deep scientific bench including Corentine M. C. Laurin, PhD, Jacques Saarbach, PhD, Zachary C. Severance, PhD, Veronika Shoba, PhD, Edward Morris, PhD, Craig Westover, PhD, Minh Tran, PhD, David Casas-Mao, PhD, Sifeng Gu, PhD, and Trinity Cookis, PhD, supported by platform and research specialists like Max Thompson, Fang-Chi Chang, MS, Nicole Wilson, MS, and Emily DeSousa, MS.
Advisors such as Lawrence G. Hamann, PhD, Andy Crew, PhD, Nicholas T. Hertz, PhD, Kumar Gondi, PhD, Steve Djuric, PhD, John Burkhardt, PhD, Margaret Dugan, M.D., Martin Babler, and Scott Forrest, PhD add another layer of pattern recognition from inside big pharma and biotech cycles.
This is what happens when the proximity is not just molecular. Capital gets closer to platform. Strategic partners get closer to pipeline. And the distance between what is “undruggable” and what is merely unsolved starts to shrink, quietly, then all at once.
